Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ViroMissile, Inc.
Seagen Inc.
MacroGenics
City of Hope Medical Center
AbbVie
M.D. Anderson Cancer Center
NeoTX Therapeutics Ltd.
GONGCHU Biotechnology Co., Ltd
Exelixis
Jonsson Comprehensive Cancer Center
University of Virginia
Incyte Corporation
AbbVie
Sotio Biotech Inc.
Carisma Therapeutics Inc
Xencor, Inc.
Pliant Therapeutics, Inc.
BioEclipse Therapeutics
Atreca, Inc.
Lebanese University
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Provectus Pharmaceuticals
AbbVie
AbbVie
Incyte Corporation
Eli Lilly and Company
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Taizhou EOC Pharma Co., Ltd.
AbbVie
Inovio Pharmaceuticals
Montefiore Medical Center
AbbVie
City of Hope Medical Center
Sun Yat-sen University
Duke University
Angiochem Inc
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)